New York K 484: Memorializing Governor Kathy Hochul to proclaim May 11-17, 2025, as Fibromyalgia Awareness Week in the State of New York

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 - This bill is not active in this session.

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
K00484 Summary:

BILL NOK00484 

&nbsp

SAME ASNo Same As

&nbsp

SPONSORSolages

&nbsp

COSPNSR

&nbsp

MLTSPNSRAngelino, Buttenschon, DeStefano, Durso, Fitzpatrick, Glick, Griffin, Hevesi, Jones, Levenberg,
 Lupardo, Maher, McDonald, McDonough, McMahon, Miller, Morinello, Novakhov, Ra, Raga, Santabarbara,
 Seawright, Sempolinski, Shimsky, Smullen, Weprin

&nbsp

&nbsp

Go to top K00484 Actions:

BILL NOK00484 

&nbsp

05/12/2025referred to calendar

05/13/2025adopted

Go to topK00484 Committee&nbspVotes:

Go to topK00484 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topK00484 Text:

Assembly Resolution No. 484

BY: M. of A. Solages

 MEMORIALIZING Governor Kathy Hochul to proclaim
 May 11-17, 2025, as Fibromyalgia Awareness Week in
 the State of New York

 WHEREAS, An estimated 10 million people in the United States, and an
estimated 3-6 percent of the world's population, generally between ages
20-50, have been diagnosed with Fibromyalgia; in the United States, this
number increases to approximately 8 percent by age 80, according to the
National Fibromyalgia Association; and

 WHEREAS, A chronic syndrome with no known prevention or cure that is
increasing at alarming rates, Fibromyalgia causes debilitating
widespread chronic pain and fatigue; has a demonstrated genetic
component; occurs in women, men, and children of all ages and
ethnicities; and demonstrates some similarities with Long COVID,
signaling an increased need for more research funding; and

 WHEREAS, Patients with Fibromyalgia often must live with widespread
pain throughout their bodies, extreme fatigue, sleep disorders,
digestive difficulties, stiffness and weakness, migraine headaches,
numbness and tingling, and impairment of memory and concentration; and

 WHEREAS, The average gap between medical research and clinical
practice is 17 years, and it often takes an average of five years to
receive a diagnosis of Fibromyalgia; and

 WHEREAS, Fibromyalgia patients are often misunderstood by the
medical, business, and education communities, primarily due to the lack
of teaching in medical schools about what is currently known regarding
this potentially disabling illness; and

 WHEREAS, Chronic pain is a risk factor for suicide, as individuals
with chronic pain are at least twice as likely to report suicidal
behaviors or to complete suicide; as part of their global initiative,
the World Health Organization recommends that a comprehensive clinical
assessment of suicidal behaviors be routinely performed on all
individuals 10 years of age or older who report having chronic pain; and

 WHEREAS, According to a fact sheet provided by the National
Fibromyalgia Association, 90% of physicians agree there is a need for
more physician oriented information, and 82% of physicians agree that
Fibromyalgia is difficult to treat with currently available tools; use
of complementary and alternative medicine is 2.5 times higher in
Fibromyalgia patients; and

 WHEREAS, The NIH reports that average direct costs above insurance,
over a three-month period, added up to $951, which could be translated
in a mean annual cost of $3804 per patient; and estimates for the total
annual direct costs per patient ranged from $1750 to $35,920 in the USA;
and

 WHEREAS, The National Fibromyalgia Association reports that over 60%
of their Fibromyalgia study participants currently use or have used CBD

for symptoms primarily to treat pain, anxiety, sleep problems, joint
stiffness, and muscle spasms, indicating a need for more rigorous
studies in order to develop guidance for physicians; and

 WHEREAS, Fibromyalgia patients often lose jobs, career promotion
opportunities, homes, and spouses or significant others due to lack of
awareness and understanding about the potentially devastating impact of
Fibromyalgia; and

 WHEREAS, The International Institute For Human Empowerment, Inc., a
nonprofit charitable organization in the Capital District of New York,
is dedicated to empowering all who face discrimination as a result of
race, gender, socioeconomic status, age, disabilities, and lifestyle
choices; and

 WHEREAS, The International Institute For Human Empowerment, Inc.,
under the leadership of Sue Shipe, PhD, developed the Fibromyalgia Task
Force of New York